ClinicalTrials.gg
RecruitingNCT07696754AR4SLNUpdated Nov 13, 2026

Augmented-Reality ICG Fluorescence Second-Look for Residual Nodal Disease After Axillary Dissection in Breast Cancer

An interventional study of Augmented-reality ICG fluorescence second-look imaging in Breast Cancer, Breast Neoplasms and Sentinel Lymph Node, sponsored by Ss. Cyril and Methodius University of Skopje. Recruiting at 1 site in North Macedonia. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Ss. Cyril and Methodius University of Skopje · Not applicable, Interventional, and Diagnostic

How we know

Updated Nov 13, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Breast Neoplasms with a site in North Macedonia — 2 open to participants now, 3 under way, 1 of them phase 3. Breast Neoplasms · North Macedonia.

Started
2026
with 1 other
No phase
2 of 11
1 open now
Registered
10th of 11
by date
Lead sponsor
2 of 11
Ss. Cyril and Methodius University of Skopje

Among the 11 studies in Breast Neoplasms with a site in North Macedonia, this one is one of 2 that started in 2026, is one of 2 with no phase, and was the 10th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

2 of the 11 studies in Breast Neoplasms with a site in North Macedonia are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in North Macedonia have not opened yet or have stopped. Only those recruiting at a site in North Macedonia →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Breast Neoplasms with a site in North Macedonia, or all of them as a file.
02

Study summary

This prospective study will enroll up to 200 patients whose clinical team has already planned an axillary lymph node dissection for breast cancer. After the surgeon completes the planned dissection and declares that no further tissue was intended for removal, a wearable augmented-reality/virtual-reality (AR/VR) system will show indocyanine-green (ICG) near-infrared fluorescence during a brief second look at the exposed surgical field. The surgeon may remove an additional fluorescent focus only after inspection under normal light and only when removal is safe and clinically appropriate. Each additional specimen will be labeled separately and examined by pathology.

The study measures the proportion of patients with an additional tumor-positive lymph node found at second look, whether such nodes change the pathological nodal category, operating time, and adverse events. The first 50 consecutive participants will form a planned descriptive device-feasibility analysis; all 200 participants will contribute to the full-cohort clinical analysis. The study does not assume that finding an additional node improves recurrence or survival.

Read the detailed description

This is a prospective, single-center, single-arm study of 200 unique participants undergoing breast cancer surgery with axillary lymph node dissection independently indicated by the clinical team. Earlier observations from an internal, unregistered protocol are not included in this study population. The first 50 consecutive enrolled participants form a prespecified descriptive device-feasibility subset; they remain part of the full 200-patient cohort and are not a separate arm.

Before AR/VR imaging, the operating surgeon records the indication and extent of the planned axillary dissection and declares that the standard procedure and inspection are complete. A brief ICG near-infrared fluorescence second look is then performed with the wearable system within the already exposed operative field. Each additional fluorescent focus receives a unique identifier, anatomic location, image or video reference when available, and a record of whether it was visible or palpable under standard lighting. The surgeon reassesses the focus under standard lighting and removes it only when safe and clinically appropriate. Each removed focus is submitted separately for pathology. Negative scans, foci left in place, interrupted scans, device failures, and added operating time are recorded.

The primary outcome remains the patient-level rate of pathology-confirmed clinically significant events (CSE) already defined in this record: at least one additional fluorescent focus not planned for removal before the second look, removed after standard-light reassessment, and confirmed to be a lymph node containing isolated tumor cells, micrometastasis, or macrometastasis. These pathology categories are reported separately. For the clinical analysis, pathology determines the nodal category using the standard dissection specimens alone and again after adding separately labeled second-look specimens. The patient-level rate of change in pathological nodal category is reported separately from the CSE rate. Any documented change in the postoperative treatment recommendation is recorded separately from a pathology finding. Procedure- and device-related adverse events are followed for 30 days.

The first 50 participants support a descriptive report of device feasibility and workflow, including scan completion, localization of additional foci, pathology of removed foci, time, and failures. The full 200-patient cohort supports estimation of CSE yield and nodal-category change with confidence intervals. There is no conventional near-infrared camera comparator. This single-arm study does not establish an improvement in recurrence, survival, or other patient outcomes.

03

Conditions studied

  • Breast Cancer
  • Breast Neoplasms
  • Sentinel Lymph Node
  • Lymphatic Metastasis

Keywords

  • indocyanine green
  • near-infrared fluorescence
  • fluorescence-guided surgery
  • augmented reality
  • axillary lymph node dissection
  • residual nodal disease
  • sentinel lymph node
  • breast cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • proven breast cancer
  • Age 18 years or older
  • Undergoing radical surgery (mastectomy or quadrantectomy) with complete axillary lymph node dissection
  • Provides written

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • chemotherapy
  • Prior breast surgery
  • Iodine or seafood allergy
  • Indocyanine green (ICG) allergy
  • Declines or is unable to provide
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    AR-ICG Second-Look

    After the operating surgeon declares the axillary lymph node dissection complete, a brief augmented-reality ICG near-infrared fluorescence re-examination of the surgical field is performed. Additional fluorescent tissue is re-assessed under standard lighting and removed only if the surgeon judges removal safe and clinically appropriate; removed tissue undergoes separate histopathology.

    Device: Augmented-reality ICG fluorescence second-look imaging

Interventions

  • DeviceAugmented-reality ICG fluorescence second-look imaging

    A wearable augmented-reality system displaying combined color and near-infrared fluorescence, with a handheld laser/white-light illuminator, used to re-examine the axillary field for residual ICG-fluorescent tissue after the surgeon declares the dissection complete. Indocyanine green is administered intraoperatively per protocol.

06

What researchers measure

Primary outcomes

  1. Patient-level rate of clinically significant events (CSE)

    Proportion of patients with at least one clinically significant event (CSE). A CSE is defined as additional fluorescent tissue identified at the second-look review after the surgeon's declared completion of the axillary dissection, not previously planned for removal, removed after re-assessment under standard lighting, and confirmed on final histopathology to be a lymph node containing tumor (isolated tumor cells, micrometastasis, or macrometastasis).

    Time frame: From intraoperative second-look review to final histopathology (up to approximately 2 weeks after surgery)

Secondary outcomes

  1. Distribution of additional fluorescent findings by tissue category

    Number of additional fluorescent findings classified on histopathology as tumor-positive lymph node, tumor-negative lymph node, or non-nodal tissue (e.g., fibro-adipose tissue or dye leakage).

    Time frame: Final histopathology (up to approximately 2 weeks after surgery)

  2. Anatomic location of additional fluorescent findings

    Anatomic location of each additional fluorescent finding, recorded as axillary level I, II, or III; interpectoral (Rotter); internal mammary; or other.

    Time frame: Intraoperative (day of surgery)

  3. Nodal stage migration

    Patient-level proportion whose pathological nodal category changes when separately labeled, pathology-confirmed second-look lymph nodes are added to the standard axillary dissection specimens. Determine pN first from the standard specimens alone and then from all specimens using the applicable breast cancer staging rules. Report the direction and category of each change; report isolated tumor cells separately and do not count them as positive nodes for pN thresholds.

    Time frame: Final histopathology (up to approximately 2 weeks after surgery)

  4. Added operative time for the second-look review

    Additional operative time required to perform the second-look review, in minutes.

    Time frame: Intraoperative (day of surgery)

  5. Procedure- or device-related adverse events

    Number of participants with adverse events related to the study procedure or device.

    Time frame: Through 30 days after surgery

  6. AR/VR second-look technical completion rate

    Proportion of participants in whom the planned AR/VR ICG second-look scan is completed with live fluorescence displayed over the exposed axillary field. Record incomplete scans, device failures, and the reason for each. Summarize this outcome for all enrolled participants and separately for the prespecified first 50 participants.

    Time frame: Intraoperative (day of surgery)

07

Study locations

1 of 1 sites recruiting
  • University Clinic for Thoracic and Vascular Surgery, Faculty of Medicine, UKIM
    Skopje, 1000, North Macedonia
    Recruiting
08

References and documents

Publications

  • de Boniface J, Filtenborg Tvedskov T, Ryden L, Szulkin R, Reimer T, Kuhn T, Kontos M, Gentilini OD, Olofsson Bagge R, Sund M, Lundstedt D, Appelgren M, Ahlgren J, Norenstedt S, Celebioglu F, Sackey H, Scheel Andersen I, Hoyer U, Nyman PF, Vikhe Patil E, Wieslander E, Dahl Nissen H, Alkner S, Andersson Y, Offersen BV, Bergkvist L, Frisell J, Christiansen P; SENOMAC Trialists' Group; SENOMAC Trialists' Group. Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases. N Engl J Med. 2024 Apr 4;390(13):1163-1175. doi: 10.1056/NEJMoa2313487. PubMed 38598571 ↗
  • Xiong X, Zheng LW, Ding Y, Chen YF, Cai YW, Wang LP, Huang L, Liu CC, Shao ZM, Yu KD. Breast cancer: pathogenesis and treatments. Signal Transduct Target Ther. 2025 Feb 19;10(1):49. doi: 10.1038/s41392-024-02108-4. PubMed 39966355 ↗
  • Donker M, van Tienhoven G, Straver ME, Meijnen P, van de Velde CJ, Mansel RE, Cataliotti L, Westenberg AH, Klinkenbijl JH, Orzalesi L, Bouma WH, van der Mijle HC, Nieuwenhuijzen GA, Veltkamp SC, Slaets L, Duez NJ, de Graaf PW, van Dalen T, Marinelli A, Rijna H, Snoj M, Bundred NJ, Merkus JW, Belkacemi Y, Petignat P, Schinagl DA, Coens C, Messina CG, Bogaerts J, Rutgers EJ. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial. Lancet Oncol. 2014 Nov;15(12):1303-10. doi: 10.1016/S1470-2045(14)70460-7. Epub 2014 Oct 15. PubMed 25439688 ↗
  • Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelemen PR, Ollila DW, Hansen NM, Whitworth PW, Blumencranz PW, Leitch AM, Saha S, Hunt KK, Morrow M. Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA. 2017 Sep 12;318(10):918-926. doi: 10.1001/jama.2017.11470. PubMed 28898379 ↗

Individual participant data

Plan to share: No — This is a single-center study of up to 200 participants. Individual participant data are not planned to be shared. De-identified data may be made available from the principal investigator on reasonable request, subject to institutional approval.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Oct 2029, 35 months later.

Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 35 months is close to that.

Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 6, 2026: start Jul 2026 → Nov 2026, primary completion Jul 2027 → Oct 2029 and completion Dec 2027 → Nov 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2026
First posted
Jul 10, 2026
StartEst.
Nov 2026was Jul 2026
Primary completionEst.
Oct 2029was Jul 2027
CompletionEst.
Nov 2029was Dec 2027
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 13, 2026
Sites
University Clinic for Thoracic and Vascular Surgery, Faculty of Medicine, UKIM is now Recruiting
Nov 13, 2026
Start date
Jul 10, 2026→Nov 2026
Nov 6, 2026
Primary completion
Jul 1, 2027→Oct 2029
Nov 6, 2026
Study completion
Dec 31, 2027→Nov 2029
Nov 6, 2026
Enrollment
30→200
Nov 6, 2026
Secondary outcomes
1 added, 1 description edited
What changed in the outcomes
  • AddedAR/VR second-look technical completion rateTime frame: Intraoperative (day of surgery)
  • DescriptionNodal stage migration: how it is measured was reworded
Nov 6, 2026
Show all 2 updates
  1. Nov 13, 2026
    Not yet recruiting→Recruiting
    University Clinic for Thoracic and Vascular Surgery, Faculty of Medicine, UKIM is now Recruiting
  2. Nov 6, 2026
    Start date Jul 10, 2026→Nov 2026
    Primary completion Jul 1, 2027→Oct 2029
    Study completion Dec 31, 2027→Nov 2029
    Enrollment 30→200
    Secondary outcomes 1 added, 1 description edited
    What changed in the outcomes
    • AddedAR/VR second-look technical completion rateTime frame: Intraoperative (day of surgery)
    • DescriptionNodal stage migration: how it is measured was reworded
    + 5 other changes: identifiers, verification date, description, design details and data sharing statement

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07696754
Lead sponsor
Ss. Cyril and Methodius University of Skopje
Responsible party
Borislav Kondov (Professor / Principal Investigator, Ss. Cyril and Methodius University of Skopje) — Principal investigator
First posted
Jul 10, 2026
Start date
Nov 2026 (estimated)
Primary completion
Oct 2029 (estimated)
Completion
Nov 2029 (estimated)
Last update
Nov 13, 2026

Study contacts

Borislav Kondov, MD
Contact
borislav.kondov@medf.ukim.edu.mk
+38972539003
Magdalena Bogdanovska Todorovska, MD
Contact
magdalena.todorovska@medf.ukim.edu.mk
+389709602221

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion